GOLD Pushes LABA/LAMA Class In New COPD Treatment Update
New guidelines for the treatment of COPD could change the way this serious condition is managed, with knock-on effects for pharma companies with respiratory franchises.
You may also be interested in...
US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.
Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.